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Herpes simplex encephahtis (HSE) is probably the most 
severe of the sporadic virus encephalitides. Without 
prompt and specific antiviral treatment, the disease is 
associated with mortality rates exceeding 70% and 
equally high rates of severe morbidity in those who 
survive the acute infection [1,2]. Two major clinical 
trials [3,4] demonstrated that the antiviral drug 
acyclovir, if given early in the course of the disease, 
dramatically reduced both the mortality and morbidity 
of the dsease. 
HSE typically presents as an acute neurologic 
disease associated with an initial prodrome of fever, 
headache and nausea. Altered levels of consciousness 
and a wide variety of non-specific focal neurologic 
signs are also observed. This results in a clinical 
presentation for which there is a wide differential 
diagnosis. In untreated patients HSE is rapidly pro- 
gressive, with brain edema and destruction of areas 
within the brainstem leading to death within 7 to 14 
days. As the new European guidelines on HSE discuss 
[5], the range of clinical presentations is such that the 
establishment of an early etiologic diagnosis demands 
active collaboration between the clinician and the 
diagnostic virus laboratory. 
Whilst the data derived from CT, MRI and EEG 
are important in the investigation of such patients, 
they do not provide information sufficient to allow 
an etiologic hagnosis. The new guidelines stress that 
specific etiologic diagnosis requires that cerebrospinal 
fluid (CSF) be taken (intracranial pressure permitting) 
during the acute stage of the illness. The CSF should 
be examined for HSV DNA using nucleic acid 
amplification techniques. Because the most developed 
and widely applied technology is currently the poly- 
merase chain reaction (PCR), the guidelines concen- 
trate upon this procedure whilst acknowledging that 
emerging target or signal amplification procedures such 
as NASBA, LCR or B-DNA [6] may, in time, prove 
equally useful. For PCR, the required sensitivity is 
believed to be of the order of 10 or less genome 
equivalents per 10 pL of CSF [7].  As approximately 
5% of cases of HSE are due to HSV type 2, the PCR 
test protocol should also be designed to detect both 
HSV type 1 and HSV type 2 DNA. Both single and 
nested PCR procedures have been found satisfactory. 
Experience accumulated over 6 years shows that HSV 
DNA is usually detectable at the onset of neurologic 
symptoms and that the PCR remains positive for at  
least 5 days after the start of acyclovir therapy. 
Complementary to the detection of HSV DNA in 
CSF is the detection of a specific intrathecal humoral 
immune response to the virus. Over the course of the 
infection, DNA becomes undetectable in CSF, and a 
strong and persistent intrathecal immune response 
develops. A variety of formulae, evaluated by the 
European Concerted Action of Virus Meningitis and 
Encephalitis [8] ,  can be used to quantifj this immune 
response. This is achieved by the detection of an 
increased CSF/serum quotient for HSV antibody, 
adjusted for CSF/blood-brain barrier integrity. In 
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Figure 1 Diagnostic algorithm for management of patients with suspected HSE (reproduced, with permission, fiom 
J Neurol Neurosurg Psychlatry 1996; 61: 339-45). As patients may present with raised intracranial pressure, immediate 
lumbar puncture may not be possible. In these circumstances, commencement of acyclovir therapy prior to lumbar 
puncture is warranted. 
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HSE, an antibody-specific index 21.5 is usually reached 
7-10 days after the onset of symptoms. This can be 
confirmed using isoelectric focusing and immuno- 
affinity mediated capillary blotting [8].  Virus isolation 
from CSF is usually not possible, and isolation of virus 
from peripheral sites or peripheral blood serology is 
rarely of value. The guidelines suggest that the original 
standard for diagnosis of HSE-isolation of virus 
from brain tissue obtained by biopsyshould now be 
replaced by the less invasive collection of CSF by 
lumbar puncture, with examination of the fluid initially 
by PCR and subsequently by antibody assay. Only 
where diagnosis is unresolved by these procedures or 
when there is no clinical improvement should brain 
biopsy now be considered. 
The standard treatment for HSE, namely a 10-day 
course of acyclovir given intravenously at a dosage of 
10 mg/kg every 8 h supplemented as appropriate by 
supportive therapy to reduce and prevent brain edema, 
should be initiated as early as possible in the chsease. 
Administration should not be delayed whilst diagnosis 
is pursued but should be reviewed in the light of 
laboratory results. It is emphasized that, given the 
relative safety of acyclovir, cessation of acyclovir 
therapy should only be contemplated when a definitive 
alternative diagnosis has been achieved. 
A further recommendation is that the period for 
acyclovir therapy should be extended if repeated 
lumbar puncture reveals the continued presence of 
HSV DNA in CSF, therapy being continued for as long 
as HSV DNA is detected (Figure 1). 
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